Abstract:There are two major clinical subsets of scleroderma: (i) systemic sclerosis (SSc) is a complex systemic autoimmune disorder characterized by inflammation, vasculopathy, and excessive fibrosis of the skin and multiple internal organs and (ii) localized scleroderma (LoS), also known as morphea, is confined to the skin and/or subcutaneous tissues resulting in collagen deposition and subsequent fibrosis. SSc is rare but is associated with significant morbidity and mortality compared with other rheumatic diseases. Fatal outcomes in SSc often originate from organ complications of the disease, such as lung fibrosis, pulmonary artery hypertension (PAH), and scleroderma renal crisis (SRC). Current treatment modalities in SSc have focused on targeting vascular damage, fibrosis, and regulation of inflammation as well as autoimmune responses. Some drugs previously used in an attempt to suppress fibrosis, like D-penicillamine (D-Pen) or colchicine, have been disappointing in clinical practice despite anecdotal evidence of their advantages. Some canonical medications, including glucocorticoids, immunosuppressants, and vasodilators, have had some success in treating various manifestations in SSc patients. Increasing evidence suggests that some biologic agents targeting collagen, cytokines, and cell surface molecules might have promising therapeutic effects in SSc. In recent years, hematopoietic stem cell transplantation (HSCT), mostly autologous, has made great progress as a promising treatment option in severe and refractory SSc. Due to the complexity and heterogeneity of SSc, there are currently no optimal treatments for all aspects of the disease. As for LoS, local skin-targeted therapy is generally used, including topical application of glucocorticoids or other immunomodulatory ointments and ultraviolet (UV) irradiation. In addition, systemic immunosuppressants are also utilized in several forms of LoS. Here, we comprehensively discuss current treatment options for scleroderma, encompassing old, new, and future potential treatment options. In addition, we summarize data from new clinical trials that have the potential to modify the disease process and improve long-term outcomes in SSc.

Stiff Skin Syndrome: Clinical Exploration, Pathophysiology and Therapeutic Advances in a Rare Connective Tissue Disease

Childhood Onset Progressive Skin Fibrosis and Joint Immobility

New clinical classification of stiff skin syndrome

Systemic Scleroderma: A Deep Dive into the Complexity of a Multi-System Autoimmune Connective Tissue Disease

Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidase–like 4: New Evidence from Three‐Dimensional Skin‐like Tissues

Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome

Pro-Fibrotic Phenotype in a Patient with Segmental Stiff Skin Syndrome via TGF-β Signaling Overactivation

Pathophysiology of systemic sclerosis (scleroderma)

Systemic sclerosis in adults. Part I: Clinical features and pathogenesis

Scleroderma and scleroderma-like syndromes

Stiff person syndrome

Stiff Person Spectrum Disorder: Overview With Emphasis On Head And Neck Comorbidities

Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review

A case report of integrating Chinese and Western medicine: A new era in the treatment of stiff person syndrome

Stiff-person Syndrome with Paraneoplastic Neurological Syndrome: a Case Report and Literature Review.

Clinical features, electrophysiological characteristics and treatment response in eight cases with stiff-person syndrome

A Multidisciplinary Approach as A Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario

Scleroderma therapy: clinical overview of current trends and future perspective

Pathogenesis and staging of scleroderma

Systemic sclerosis skin is a primed microenvironment for soft tissue calcification-a hypothesis

Comprehensive Analysis of Scalded Skin Syndrome: Clinical Exploration, Underlying Pathophysiology and Advanced Therapeutic Approaches